Vistagen Therapeutics (VTGN) Stock Price Up -5.8%

Vistagen Therapeutics Inc (NASDAQ:VTGN) shares rose 5.8% during mid-day trading on Monday . The company traded as high as $1.48 and last traded at $1.45. Approximately 13,309 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 1,922,024 shares. The stock had previously closed at $1.54.

VTGN has been the topic of a number of recent analyst reports. UBS Group initiated coverage on shares of Vistagen Therapeutics in a research report on Thursday, May 24th. They issued an “outperform” rating and a $6.00 price target on the stock. Zacks Investment Research reiterated a “buy” rating and issued a $1.00 price objective on shares of Vistagen Therapeutics in a research note on Saturday, April 7th. Finally, Oppenheimer began coverage on shares of Vistagen Therapeutics in a research note on Thursday, May 24th. They issued a “buy” rating and a $6.00 price objective for the company.

The company has a market cap of $33.90 million, a price-to-earnings ratio of -0.92 and a beta of 0.29.

Several large investors have recently added to or reduced their stakes in the company. Sabby Management LLC bought a new stake in shares of Vistagen Therapeutics in the 4th quarter valued at $2,352,000. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Vistagen Therapeutics by 131.6% in the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 104,414 shares of the company’s stock valued at $116,000 after acquiring an additional 59,338 shares in the last quarter. Finally, Sphera Funds Management LTD. increased its stake in shares of Vistagen Therapeutics by 17.8% in the 4th quarter. Sphera Funds Management LTD. now owns 1,247,251 shares of the company’s stock valued at $1,384,000 after acquiring an additional 188,865 shares in the last quarter. Institutional investors own 9.43% of the company’s stock.

Vistagen Therapeutics Company Profile

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit